Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml (Q57999041)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22430630%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

title

Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22430630%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

0 references

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22430630%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Margherita Fanelli

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22430630%20AND%20SRC:MED&resulttype=core&format=json

Cinzia Annatea Germinario

26 January 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22430630%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Michele Battaglia

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22430630%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

author name string

Angela Maria Vittoria Larocca

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22430630%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Monica Rutigliano

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22430630%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Antonio Vavallo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22430630%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Francesco Paolo Selvaggi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22430630%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Carlo Bettocchi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22430630%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Pasquale Ditonno

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22430630%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

publication date

16 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22430630%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22430630%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

volume

72

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22430630%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

issue

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22430630%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

page(s)

1611-1621

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22430630%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Prostate-specific antigen in the early detection of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Emerging biomarkers for the diagnosis and prognosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Blood and tissue biomarkers in prostate cancer: state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Urine biomarkers in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Emerging molecular biomarkers--blood-based strategies to detect and monitor cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Metabolic profiles of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Otto Warburg's contributions to current concepts of cancer metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Clinical applications of metabolomics in oncology: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Urine metabolomics analysis for kidney cancer detection and biomarker discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12-8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12-8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

GC/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Serum sarcosine is not a marker for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Choline metabolism in cancer: implications for diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Choline phospholipid metabolism: a target in cancer cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Non-destructive quantitation of spermine in human prostate tissue samples using HRMAS 1H NMR spectroscopy at 9.4 T.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Concepts of citrate production and secretion by prostate. 1. Metabolic relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Concepts of citrate production and secretion by prostate: 2. Hormonal relationships in normal and neoplastic prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Application of metabolomics to prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Prostate-specific antigen levels in the United States: implications of various definitions for abnormal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

Assessment of the PCA3 test for prostate cancer diagnosis: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22514

21 January 2018

Identifiers

DOI

10.1002/PROS.22514

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22430630%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference